These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 34379924)

  • 1. Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs.
    Schett G; McInnes IB; Neurath MF
    N Engl J Med; 2021 Aug; 385(7):628-639. PubMed ID: 34379924
    [No Abstract]   [Full Text] [Related]  

  • 2. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
    Nash P; Kerschbaumer A; Dörner T; Dougados M; Fleischmann RM; Geissler K; McInnes I; Pope JE; van der Heijde D; Stoffer-Marx M; Takeuchi T; Trauner M; Winthrop KL; de Wit M; Aletaha D; Baraliakos X; Boehncke WH; Emery P; Isaacs JD; Kremer J; Lee EB; Maksymowych WP; Voshaar M; Tam LS; Tanaka Y; van den Bosch F; Westhovens R; Xavier R; Smolen JS
    Ann Rheum Dis; 2021 Jan; 80(1):71-87. PubMed ID: 33158881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
    Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
    Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
    Fragoulis GE; McInnes IB; Siebert S
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Indications and efficacy of biologics in inflammatory arthritis].
    Combe B
    Bull Acad Natl Med; 2012 Oct; 196(7):1279-92; discussion 1293. PubMed ID: 23815014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the role of Interleukin 17 in rheumatologic autoimmune diseases.
    Konya C; Paz Z; Apostolidis SA; Tsokos GC
    Cytokine; 2015 Oct; 75(2):207-15. PubMed ID: 26028353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases.
    Williams RO; Paleolog E; Feldmann M
    Curr Opin Pharmacol; 2007 Aug; 7(4):412-7. PubMed ID: 17627887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis.
    Kragstrup TW; Andersen T; Heftdal LD; Hvid M; Gerwien J; Sivakumar P; Taylor PC; Senolt L; Deleuran B
    Front Immunol; 2018; 9():2226. PubMed ID: 30319661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis.
    Vandooren B; Noordenbos T; Ambarus C; Krausz S; Cantaert T; Yeremenko N; Boumans M; Lutter R; Tak PP; Baeten D
    Arthritis Rheum; 2009 Apr; 60(4):966-75. PubMed ID: 19333931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of Interleukin-32 in autoimmunity.
    de Albuquerque R; Komsi E; Starskaia I; Ullah U; Lahesmaa R
    Scand J Immunol; 2021 Feb; 93(2):e13012. PubMed ID: 33336406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine-modifying therapies in immune disorders.
    Romanelli F
    JAAPA; 2002 Feb; 15(2):25-8, 31-4. PubMed ID: 11917757
    [No Abstract]   [Full Text] [Related]  

  • 12. JAK-STAT inhibitors for the treatment of immunomediated diseases.
    Serra López-Matencio JM; Morell Baladrón A; Castañeda S
    Med Clin (Barc); 2019 May; 152(9):353-360. PubMed ID: 30527218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
    Coates LC; FitzGerald O; Helliwell PS; Paul C
    Semin Arthritis Rheum; 2016 Dec; 46(3):291-304. PubMed ID: 27388027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunosuppressive therapeutic modalities in chronic polyarthritis].
    Lorenz HM; Geiler T; Kalden JR
    Internist (Berl); 1997 Jun; 38(6):532-40. PubMed ID: 9264998
    [No Abstract]   [Full Text] [Related]  

  • 15. Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
    Haberman R; Axelrad J; Chen A; Castillo R; Yan D; Izmirly P; Neimann A; Adhikari S; Hudesman D; Scher JU
    N Engl J Med; 2020 Jul; 383(1):85-88. PubMed ID: 32348641
    [No Abstract]   [Full Text] [Related]  

  • 16. IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential.
    Boutet MA; Nerviani A; Pitzalis C
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus kinases to jakinibs: from basic insights to clinical practice.
    Gadina M; Le MT; Schwartz DM; Silvennoinen O; Nakayamada S; Yamaoka K; O'Shea JJ
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i4-i16. PubMed ID: 30806710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-17A Interweaves the Skeletal and Immune Systems.
    Tang M; Lu L; Yu X
    Front Immunol; 2020; 11():625034. PubMed ID: 33613566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
    Bonelli M; Kerschbaumer A; Kastrati K; Ghoreschi K; Gadina M; Heinz LX; Smolen JS; Aletaha D; O'Shea J; Laurence A
    Ann Rheum Dis; 2024 Jan; 83(2):139-160. PubMed ID: 37923366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases.
    Leng RX; Pan HF; Tao JH; Ye DQ
    Expert Opin Ther Targets; 2011 Feb; 15(2):119-26. PubMed ID: 21073280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.